Engineering light-initiated afterglow lateral flow immunoassay for infectious disease diagnostics

Biosens Bioelectron. 2022 Sep 15:212:114411. doi: 10.1016/j.bios.2022.114411. Epub 2022 May 20.

Abstract

The pandemic of highly contagious diseases has put forward urgent requirements for high sensitivity and adaptive capacity of point-of-care testing (POCT). Herein, for the first time, we report an aggregation-induced emission (AIE) dye-energized light-initiated afterglow nanoprobes (named LiAGNPs), implemented onto a lateral flow immunoassay (LFIA) test strip, for diagnosis of two highly contagious diseases, human immunodeficiency virus (HIV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as model validation. The primary working mechanism relies on the cyclically generated singlet oxygen (1O2)-triggered time-resolved luminescent signals of LiAGNPs in which AIE dyes (TTMN) and chemiluminescent substrates (SO) are loaded. The designed LiAGNPs were found 2-fold and 32-fold sensitive than the currently used Eu(III)-based time-resolved fluorescent nanoparticles and gold nanoparticles in lateral flow immunoassay (LFIA), respectively. In addition, the extra optical behaviors of nude color and fluorescence of LiAGNPs enable the LFIA platform with the capability of the naked eye and fluorescent detection to satisfy the applications under varying scenarios. In short, the versatile LiAGNPs have great potential as a novel time-resolved reporter in enhancing detection sensitivity and application flexibility with LFIA platform for rapid but sensitive infectious disease diagnostics.

Keywords: Afterglow; HIV; Infectious disease; Lateral flow immunoassay; SARS-CoV-2.

MeSH terms

  • Biosensing Techniques*
  • COVID-19* / diagnosis
  • Gold
  • Humans
  • Immunoassay
  • Metal Nanoparticles*
  • SARS-CoV-2

Substances

  • Gold